Neumora's early-stage schizophrenia drug study put on hold (updated)

Neumora Therapeutics

15/04/2024 11:52

(Adds details on pre-clinical study data and early-stage study
in paragraphs 2-5)
       April 15 (Reuters) - Neumora Therapeutics  NMRA.O  said
on Monday the U.S. Food and Drug Administration (FDA) had placed
a clinical hold on early-stage study of its experimental
schizophrenia drug, sending its shares down more than 23% in
premarket trading.
    The FDA decided to place the study on hold after recently
available pre-clinical data showed uncontrollable muscle
contractions or convulsions in rabbits. The company has now
paused the early-stage study. 
    About 30 participants had been dosed in the early-stage
study with no evidence of convulsions observed in any
participant, the company said. 
    Neumora is working with the FDA to resolve the clinical
hold.
    The company that is backed by Amgen  AMGN.O  and Japan's
SoftBank  9434.T  debuted on the Nasdaq in September. 
         

 (Reporting by Sneha S K in Bengaluru; Editing by Shinjini
Ganguli)
 ((Sneha.SK@thomsonreuters.com;))